This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with…

Neuroendocrine Tumor Grade 2Neuroendocrine Tumors

~Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT04339036

Phase 2

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatm…

Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2

~Estimated

~$10 – $6,250

University of IowaNCT06395402